CLAIMS

1. An oral sustained-release dosage form comprising:

ruxolitinib phosphate, and

a sustained-release matrix former, which is a cellulosic ether;

wherein the ruxolitinib phosphate is present in the dosage form in an amount of 10 to 60 mg on a free base basis;

wherein the dosage form is suitable for oral administration; and

wherein administration of the dosage form to a human results in a ratio of mean peak plasma concentration (C_{max}) to mean 12-hour plasma concentration (C_{12h}) of ruxolitinib of 10 or less, and

wherein administration of the dosage form to a human results in a mean half-life ($t_{1/2}$) of from 3.5 hours to 11 hours.

2. The oral sustained-release dosage form of Claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 10 mg on a free base basis.

3. The oral sustained-release dosage form of Claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 20 mg on a free base basis.

4. The oral sustained-release dosage form of Claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 30 mg on a free base basis.

5. The oral sustained-release dosage form of Claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 40 mg on a free base basis.

6. The oral sustained-release dosage form of Claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 50 mg on a free base basis.

7. The oral sustained-release dosage form of Claim 1, wherein administration of the dosage form to a human results in a ratio of mean peak plasma concentration (C_{max}) to mean 12-hour plasma concentration (C_{12h}) of ruxolitinib of 1 to 10.

8. The oral sustained-release dosage form of Claim 1, wherein administration of the sustained-release dosage form to a human results in a ratio of mean peak plasma concentration (C_{max}) to mean 12-hour plasma concentration (C_{12h}) of ruxolitinib of 2 to 7.

9. The oral sustained-release dosage form of Claim 1, wherein administration of the dosage form to a human results in a mean half-life ($t_{1/2}$) of from 4 hours to 8 hours.

10. The oral sustained-release dosage form of Claim 1, wherein the dosage form is a tablet.

11. The oral sustained-release dosage form of Claim 1, wherein the dosage form is a capsule.

12. The oral sustained-release dosage form of Claim 1, wherein administration of the dosage form to a human results in a mean time to peak plasma concentration (t_{max}) of ruxolitinib of 1.5 hours to 5 hours.

13. An oral sustained-release dosage form comprising:

ruxolitinib phosphate, and

a sustained-release matrix former, which is hydroxypropyl methylcellulose;

wherein the ruxolitinib phosphate is present in the dosage form in an amount of 10 to 60 mg on a free base basis;

wherein the dosage form is suitable for oral administration;

wherein administration of the dosage form to a human results in a ratio of mean peak plasma concentration (C_{max}) to mean 12-hour plasma concentration (C_{12h}) of ruxolitinib of 10 or less, and

wherein administration of the dosage form to a human results in a mean half-life ($t_{1/2}$) of from 3.5 hours to 11 hours.

14. Use of the oral sustained-release dosage form of any one of Claims 1 to 8 and 13, in the manufacture of a medicament for the treatment of a disease selected from myelofibrosis, polycythemia vera, and graft versus host disease, wherein the oral sustained-release dosage form is to be administered once per day.

15. The use of Claim 14, wherein the disease is myelofibrosis.

16. The use of claim 15, wherein the myelofibrosis is primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (PV-MF), or post-essential thrombocythemia myelofibrosis (post ET-MF).

17. The use of claim 14, wherein the disease is polycythemia vera.

18. The use of claim 14, wherein the disease is graft versus host disease.